文献速递冠心病血脂与心血管预防

癌症患者及幸存者的冠状动脉粥样硬化:美国心脏协会科学声明

Coronary Atherosclerosis in Patients With Cancer and Survivors: A Scientific Statement From the American Heart Association.
PubMed 文献 · Circulation · 2026-02-09

该科学声明由美国心脏协会发布,旨在综合癌症与冠状动脉粥样硬化相互作用的证据。声明指出共享危险因素和重叠病理生理机制(如炎症、克隆性造血)加速动脉粥样硬化,且肿瘤治疗(化疗、靶向、免疫、放疗)促进内皮功能障碍和斑块不稳定。声明强调无创影像用于早期检测和风险分层,并因出血和血栓风险升高而推荐个体化PCI术后药物及缩短双联抗血小板疗程。

要点

  • 癌症与动脉粥样硬化共享危险因素和机制,互相加剧风险。
  • 肿瘤治疗(化疗、靶向、免疫、放疗)加速动脉粥样硬化和斑块不稳定。
  • 无创影像用于癌症人群CAD早期检测和风险分层,PCI术后需个体化抗栓治疗。

核心结论

  • 冠状动脉粥样硬化与癌症存在共享病理生物学,需要整合的多学科方法来筛查、诊断和管理。

研究设计与样本

  • 美国心脏协会科学声明,综合现有证据,未报告系统检索方法或样本量。

主要发现

  • 传统危险因素(吸烟、衰老、肥胖、高血压、糖尿病)和新型标志物(如意义未明的克隆性造血)同时增加癌症和冠状动脉粥样硬化风险。
  • 肿瘤治疗(蒽环类、5-氟尿嘧啶、酪氨酸激酶抑制剂、雄激素剥夺、芳香化酶抑制剂、免疫检查点抑制剂、放疗)通过内皮功能障碍和斑块不稳定加速动脉粥样硬化。
  • 炎症过程在动脉粥样硬化形成中起核心作用,并被肿瘤治疗进一步加速。
  • 无创影像(心脏CT、核素成像、心脏磁共振、超声心动图)可用于癌症人群CAD的早期检测、风险分层和监测。
  • 有创成像技术可用于指导血运重建决策。

关键数值与推荐

  • 癌症患者PCI术后出血和血栓风险升高,强调个体化管理药物和缩短双联抗血小板疗程。
  • 声明未提供具体数值阈值、剂量或推荐等级。

临床怎么用

  • 对癌症患者和幸存者应使用无创影像进行CAD早期检测和风险分层。
  • PCI术后抗栓治疗需个体化,考虑缩短双联抗血小板疗程以平衡出血和血栓风险。
  • 筛查和管理需要多学科团队整合肿瘤学和心脏病学。

局限性

  • 声明指出存在知识缺口,需要更多证据来改善癌症患者动脉粥样硬化性心血管疾病的风险分层。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

There is an emerging convergence between atherosclerotic cardiovascular disease and cancer, driven by shared risk factors and overlapping pathophysiologic mechanisms. Traditional factors, such as smoking, aging, obesity, hypertension, and diabetes, alongside novel markers, such as clonal hematopoiesis of indeterminate potential, not only predispose individuals to both malignancies and coronary atherosclerosis but also amplify the risk of cardiotoxicity from cancer therapies. Inflammatory processes play a central role in atherogenesis, a process further accelerated by oncologic treatments-including chemotherapy (eg, anthracyclines, 5-fluorouracil), targeted and hormone therapies (eg, tyrosine kinase inhibitors, androgen deprivation, aromatase inhibitors), immune checkpoint inhibitors, and radiation therapy (RT)-that contribute to endothelial dysfunction and plaque instability. This scientific statement synthesizes the evidence on the interplay between cancer and coronary atherosclerosis, highlighting advances in noninvasive imaging modalities (ie, cardiac CT, nuclear imaging, cardiac magnetic resonance, echocardiography) for early detection, risk stratification, and surveillance of coronary artery disease in oncologic populations, and examines the role of invasive imaging techniques in guiding revascularization decisions. Given the elevated bleeding and thrombotic risks in these patients, individualized management of post-percutaneous coronary intervention medications and abbreviated dual antiplatelet therapy regimens is emphasized. This scientific statement also addresses knowledge gaps and reinforces the need for more evidence to improve risk stratification for atherosclerotic cardiovascular disease in patients with cancer. The shared pathobiology between coronary atherosclerosis and cancer necessitates an integrated, multidisciplinary approach to screening, diagnosis, and management.

来源:Circulation,查看原文。版权归原作者所有。

引用

  1. Zhang L, Iliescu C, Ferencik M, et al. Coronary Atherosclerosis in Patients With Cancer and Survivors: A Scientific Statement From the American Heart Association. Circulation. 2026. PMID: 41657216. doi:10.1161/CIR.0000000000001391

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。